{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:40:50Z","timestamp":1780407650474,"version":"3.54.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Pralatrexate is a folate antagonist that selectively enters cells expressing reduced folate carrier type 1 and competitively inhibits dihydrofolate reductase, leading to interruption of RNA synthesis, DNA replication, and apoptosis. This phase 1 study was conducted to evaluate the maximum tolerated dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen (part 1) and the response and pharmacokinetics of 6 cycles of this combination (CHOP\u00a0+ Folotyn 30\u00a0mg\/m2 [Fol-CHOP]) in patients with newly diagnosed peripheral T-cell lymphoma (PTCL). In part 1, on days 1 and 8 of each cycle, patients were treated with 10, 15, 20, 25, or 30\u00a0mg\/m2 of pralatrexate in combination with CHOP, per dose escalation, in 5 sequential cohorts. No patients experienced DLTs in cohorts 1, 2, 3, 4, and 5. The pralatrexate dose of 30\u00a0mg\/m2 was selected to be combined with CHOP for part 2 and administered to 33 additional patients in the expansion cohort. At the MTD, the Fol-CHOP regimen was generally well tolerated in patients with PTCL, with an overall response rate (ORR) of 83.9% (20 complete response and 6 partial response), as assessed by treating investigators. Thirty-five patients (67.3%) experienced grade 3\/4 treatment-emergent adverse events, the most common of which were anemia (21.2%), neutropenia (19.2%), febrile neutropenia (11.5%), fatigue, mucosal inflammation, nausea, and vomiting (7.7% each). In conclusion, Fol-CHOP was found to be a safe and effective treatment for newly diagnosed PTCL and deemed worthy of further investigation. This trial was registered at www.ClinicalTrials.gov as #NCT02594267.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011095","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T21:11:24Z","timestamp":1701292284000},"page":"353-364","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1646-813X","authenticated-orcid":false,"given":"Swaminathan P.","family":"Iyer","sequence":"first","affiliation":[{"name":"1Department of Lymphoma\/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"3Lymphoma Program, University of Pennsylvania School of Medicine. Philadelphia, PA"},{"name":"4Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"issue":"1","key":"2024011922315350200_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Non-Hodgkin's Lymphoma Classification Project. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"issue":"25","key":"2024011922315350200_bib2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"2024011922315350200_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/asheducation-2011.1.515","article-title":"Therapies for peripheral T-cell lymphomas","volume":"2011","author":"Savage","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2024011922315350200_bib4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1023\/A:1008439620513","article-title":"Report of the European Task Force on lymphomas: workshop on peripheral T-cell lymphomas","volume":"9","author":"Campo","year":"1998","journal-title":"Ann Oncol"},{"issue":"2","key":"2024011922315350200_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"issue":"25","key":"2024011922315350200_bib6","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"2024011922315350200_bib7","doi-asserted-by":"crossref","first-page":"624040","DOI":"10.1155\/2010\/624040","article-title":"Peripheral T-cell lymphoma: review and updates of current management strategies","volume":"2010","author":"Tang","year":"2010","journal-title":"Adv Hematol"},{"key":"2024011922315350200_bib8","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A\u00a0systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"issue":"3","key":"2024011922315350200_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"4","key":"2024011922315350200_bib10","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/10428194.2013.816700","article-title":"Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)","volume":"55","author":"Ganjoo","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2024011922315350200_bib11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3346\/jkms.2004.19.6.820","article-title":"Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma","volume":"19","author":"Kim","year":"2004","journal-title":"J\u00a0Korean Med Sci"},{"issue":"14","key":"2024011922315350200_bib12","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024011922315350200_bib13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal Propel study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2024011922315350200_bib14","first-page":"2646","article-title":"A\u00a0randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"issue":"10168","key":"2024011922315350200_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"2024011922315350200_bib16","author":"Folotyn","year":"2018"},{"key":"2024011922315350200_bib17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hon.2438_113","article-title":"Case match control analysis of propel reveals a survival advantage for patients with relapsed PTCL receiving pralatrexate: a novel approach to benchmark drugs in rare diseases","volume":"35","author":"O'Connor","year":"2017","journal-title":"Hematol Oncol"},{"issue":"8","key":"2024011922315350200_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Lumiere study investigators. randomized phase III study of alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O'Connor","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2024011922315350200_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2024011922315350200_bib20","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2018-99-119684","article-title":"Management of mucositis with the use of leucovorin as adjunct to pralatrexate in treatment of peripheral t-cell lymphomas (PTCL) \u2014 results from a prospective multicenter phase 2 clinical trial","volume":"132","author":"Shustov","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2024011922315350200_bib21","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1096\/fasebj.5.12.1916088","article-title":"Compartmentation of folate-mediated one-carbon metabolism in eukaryotes","volume":"5","author":"Appling","year":"1991","journal-title":"FASEB J"},{"issue":"5","key":"2024011922315350200_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024011922315350200_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Final analysis of the Ro-CHOP phase III study (conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma","volume":"40","author":"Bachy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024011922315350200_bib24","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"issue":"5","key":"2024011922315350200_bib25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bjh.14763","article-title":"The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers","volume":"178","author":"Li","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"2024011922315350200_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2217\/fon-2021-1032","article-title":"The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review","volume":"18","author":"Ashaye","year":"2022","journal-title":"Future Oncol"},{"issue":"1","key":"2024011922315350200_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"18","key":"2024011922315350200_bib28","first-page":"2194","article-title":"Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024011922315350200_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-134398","article-title":"The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma","volume":"136","author":"Horwitz","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2024011922315350200_bib30","doi-asserted-by":"crossref","first-page":"pky038","DOI":"10.1093\/jncics\/pky038","article-title":"Strategy for assessing new drug value in orphan diseases: an international case match control analysis of the PROPEL study","volume":"2","author":"O'Connor","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"5","key":"2024011922315350200_bib31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/353\/2210452\/blooda_adv-2023-011095-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/353\/2210452\/blooda_adv-2023-011095-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T22:32:14Z","timestamp":1705703534000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/2\/353\/506337\/Pralatrexate-injection-combined-with-CHOP-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011095","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}